Related Experiment Videos

Is risk factor control and guideline-based medical therapy optimal in patients with nonobstructive coronary artery

Tarun W Dasari1, Harsh Golwala, Michael Koehler

  • 1Department of Internal Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA. dasaritarun@gmail.com

The American Journal of the Medical Sciences
|October 10, 2012
PubMed

Insights

Patients with nonobstructive coronary artery disease (NOCAD) receive less evidence-based secondary prevention compared to those with obstructive coronary artery disease (OCAD). This highlights a gap in care for NOCAD patients, necessitating improved treatment strategies.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Health Services Research

Background:

  • Secondary prevention strategies are crucial for managing coronary artery disease (CAD).
  • Evidence-based guidelines recommend aggressive risk factor modification for CAD patients.
  • This study compares the utilization of these strategies in patients with nonobstructive CAD (NOCAD) versus obstructive CAD (OCAD).

Purpose of the Study:

  • To compare the use of evidence-based secondary prevention strategies in patients with NOCAD and OCAD.
  • To identify disparities in medical therapy utilization between these two patient groups.

Main Methods:

  • Retrospective analysis of patients undergoing coronary angiography between January 2006 and June 2006.
  • Comparison of demographic, clinical, and treatment data at baseline and 1-year follow-up.
  • Stratification of patients into NOCAD and OCAD groups.

Main Results:

  • Patients with NOCAD had lower prevalence of hypertension and heart failure.
  • Statin use was significantly lower at baseline and 1 year in the NOCAD group compared to OCAD.
  • Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers was also significantly lower in the NOCAD group at 1 year.

Conclusions:

  • Evidence-based medical therapy is underutilized in patients with NOCAD compared to OCAD.
  • Healthcare providers need increased awareness to implement secondary prevention strategies more effectively in NOCAD patients.
  • A unified approach is necessary to address the deficiencies in secondary prevention for nonobstructive coronary artery disease.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...